Literature DB >> 1929339

Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination.

A M Sugar1.   

Abstract

Mice infected intravenously with Candida albicans were treated with SCH 39304, a new triazole antifungal compound, amphotericin B, or both. Two dose levels of each drug were evaluated in an attempt to identify potential helpful or harmful effects on survival and kidney colony counts. Contrary to theoretical predictions, combination therapy was not antagonistic and some additive or synergistic effects were observed. The results obtained in this study suggest that antagonism between polyene and azole antifungal drugs is not inevitable and that additive or synergistic effects may be possible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929339      PMCID: PMC245239          DOI: 10.1128/AAC.35.8.1669

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Efficacy of SCH39304 in murine cryptococcosis.

Authors:  B I Restrepo; J Ahrens; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  The effect of antacid and cimetidine on the oral absorption of the antifungal agent SCH 39304.

Authors:  T Kosoglou; G P Perentesis; M B Affrime; C C Lin; P Mojaverian; E Radwanski; P H Vlasses
Journal:  J Clin Pharmacol       Date:  1990-07       Impact factor: 3.126

3.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.

Authors:  J R Perfect; K A Wright; M M Hobbs; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.

Authors:  A M Sugar; M Picard; L Noble
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis.

Authors:  K V Clemons; L H Hanson; A M Perlman; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

7.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.

Authors:  A Schaffner; P G Frick
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

8.  Effect of cilofungin (LY121019), a fungal cell wall synthesis inhibitor, on interactions of Candida albicans with human neutrophils.

Authors:  T Meshulam; S M Levitz; R D Diamond; A M Sugar
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

  8 in total
  14 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 3.  Use of amphotericin B with azole antifungal drugs: what are we doing?

Authors:  A M Sugar
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

4.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.

Authors:  Anthony Cacciapuoti; Maya Gurnani; Judith Halpern; Christine Norris; Reena Patel; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis.

Authors:  E J Anaissie; R Hachem; N C Karyotakis; A Gokaslan; M C Dignani; L C Stephens; C K Tin-U
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  Antifungal activity of 3'-deoxyadenosine (cordycepin).

Authors:  A M Sugar; R P McCaffrey
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B.

Authors:  A M Sugar; M Salibian; L Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Candida albicans cell walls contain the fluorescent cross-linking amino acid dityrosine.

Authors:  E H Smail; P Briza; A Panagos; L Berenfeld
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans.

Authors:  G M Scalarone; Y Mikami; N Kurita; K Yazawa; M Miyaji
Journal:  Mycopathologia       Date:  1992-12       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.